You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Pharmaceutical supply chain risk assessment in Iran using analytic hierarchy process (AHP) and simple additive weighting (SAW) methods
|
|---|---|
| Published in |
Journal of Pharmaceutical Policy and Practice, February 2015
|
| DOI | 10.1186/s40545-015-0029-3 |
| Pubmed ID | |
| Authors |
Mona Jaberidoost, Laya Olfat, Alireza Hosseini, Abbas Kebriaeezadeh, Mohammad Abdollahi, Mahdi Alaeddini, Rassoul Dinarvand |
| Abstract |
Pharmaceutical supply chain is a significant component of the health system in supplying medicines, particularly in countries where main drugs are provided by local pharmaceutical companies. No previous studies exist assessing risks and disruptions in pharmaceutical companies while assessing the pharmaceutical supply chain. Any risks affecting the pharmaceutical companies could disrupt supply medicines and health system efficiency. The goal of this study was the risk assessment in pharmaceutical industry in Iran considering process's priority, hazard and probability of risks. The study was carried out in 4 phases; risk identification through literature review, risk identification in Iranian pharmaceutical companies through interview with experts, risk analysis through a questionnaire and consultation with experts using group analytic hierarchy process (AHP) method and rating scale (RS) and risk evaluation of simple additive weighting (SAW) method. In total, 86 main risks were identified in the pharmaceutical supply chain with perspective of pharmaceutical companies classified in 11 classes. The majority of risks described in this study were related to the financial and economic category. Also financial management was found to be the most important factor for consideration. Although pharmaceutical industry and supply chain were affected by current political conditions in Iran during the study time, but half of total risks in the pharmaceutical supply chain were found to be internal risks which could be fixed by companies, internally. Likewise, political status and related risks forced companies to focus more on financial and supply management resulting in less attention to quality management. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 2 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Science communicators (journalists, bloggers, editors) | 2 | 100% |
| Members of the public | 1 | 50% |
Mendeley readers
The data shown below were compiled from readership statistics for 271 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| India | 2 | <1% |
| Malaysia | 1 | <1% |
| Iran, Islamic Republic of | 1 | <1% |
| Unknown | 267 | 99% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 50 | 18% |
| Student > Bachelor | 34 | 13% |
| Student > Ph. D. Student | 26 | 10% |
| Lecturer | 18 | 7% |
| Researcher | 15 | 6% |
| Other | 42 | 15% |
| Unknown | 86 | 32% |
| Readers by discipline | Count | As % |
|---|---|---|
| Engineering | 55 | 20% |
| Business, Management and Accounting | 41 | 15% |
| Pharmacology, Toxicology and Pharmaceutical Science | 18 | 7% |
| Social Sciences | 8 | 3% |
| Computer Science | 8 | 3% |
| Other | 37 | 14% |
| Unknown | 104 | 38% |
Attention Score in Context
This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 29 April 2015.
All research outputs
#13,941,015
of 22,800,560 outputs
Outputs from Journal of Pharmaceutical Policy and Practice
#251
of 405 outputs
Outputs of similar age
#129,512
of 255,860 outputs
Outputs of similar age from Journal of Pharmaceutical Policy and Practice
#9
of 12 outputs
Altmetric has tracked 22,800,560 research outputs across all sources so far. This one is in the 37th percentile – i.e., 37% of other outputs scored the same or lower than it.
So far Altmetric has tracked 405 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 11.3. This one is in the 35th percentile – i.e., 35% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 255,860 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 47th percentile – i.e., 47% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 12 others from the same source and published within six weeks on either side of this one. This one is in the 8th percentile – i.e., 8% of its contemporaries scored the same or lower than it.